Study of ONO-8577 in Patients With Overactive Bladder

• Status: Completed
• Trial end date: 2017-09-26
• Target enrollment: 0
• Participant gender: All

Summary

The objective of the study is to evaluate the efficacy and safety of ONO-8577 compared to combination of solifenacin succinate and mirabegron or placebo for overactive bladder

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ono Pharmaceutical Co. Ltd
• Treatments: Mirabegron; Solifenacin Succinate

Criteria

Inclusion Criteria:

• Patient with symptoms of overactive bladder for ≥6 months

Exclusion Criteria:

• Patient with genuine stress incontinence, or with stress-predominant mixed urinary incontinence

• Patient who has never experienced urge urinary incontinence during disease duration of overactive bladder